FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549069008> ?p ?o ?g. }

• W2549069008 endingPage "87430" @default.
• W2549069008 startingPage "87417" @default.
• W2549069008 abstract "// Erin N. McAndrew 1, 2 , Chloe C. Lepage 1, 2 , Kirk J. McManus 1, 2 1 University of Manitoba, Department of Biochemistry & Medical Genetics, Winnipeg, Manitoba, Canada 2 Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada Correspondence to: Kirk J. McManus, email: Kirk.McManus@umanitoba.ca Keywords: cancer, RAD54B, PARP1, synthetic lethality, precision medicine Received: October 12, 2016      Accepted: November 07, 2016      Published: November 26, 2016 ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer-related death throughout the world. Despite improved screening efforts, most CRCs are diagnosed at late stages when surgery alone is not curative. Moreover, the low 5-year survival rate (~8-13%) for those living with stage IV CRC highlights the need for better treatment options. Many current chemotherapeutic approaches are non-specific and associated with side effects due to their tendency to target both normal and cancer cells. To address this issue, synthetic lethal (SL) approaches are now being explored in cancer and are defined as the lethal combination of two independently viable mutations/deletions. From a therapeutic perspective, SL interactors of genes mutated in cancer serve as candidate drug targets. The present study focuses on RAD54B , a gene that is aberrantly expressed in many cancer types, including CRC. We show that PARP1 silencing or inhibition (BMN673 or Olaparib) leads to selective killing within RAD54B -deficient cells relative to controls, and is accompanied by increases in γ-H2AX (a surrogate marker of DNA double strand breaks) and cleaved Caspase-3 (an apoptotic indicator). We further show that BMN673 synergizes with LCS-1 (an inhibitor of an established RAD54B SL interactor) to induce enhanced killing in RAD54B -deficient cells. Collectively, these data identify RAD54B and PARP1 as SL interactors, and thus reveal PARP1 as a novel candidate drug target in RAD54B -deficient CRCs. These findings further show that combinatorial chemotherapies involving multiple SL targets may promote synergistic killing within cancer cells, a strategy that may hold potential in many cancer contexts." @default.
• W2549069008 created "2016-11-30" @default.
• W2549069008 creator A5030293228 @default.
• W2549069008 creator A5045343897 @default.
• W2549069008 creator A5084704940 @default.
• W2549069008 date "2016-11-26" @default.
• W2549069008 modified "2023-10-16" @default.
• W2549069008 title "The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition" @default.
• W2549069008 cites W1018331845 @default.
• W2549069008 cites W1544851750 @default.
• W2549069008 cites W1861891742 @default.
• W2549069008 cites W1965707365 @default.
• W2549069008 cites W1971500514 @default.
• W2549069008 cites W1973268287 @default.
• W2549069008 cites W1979736396 @default.
• W2549069008 cites W1985638918 @default.
• W2549069008 cites W1985775217 @default.
• W2549069008 cites W1986471561 @default.
• W2549069008 cites W2000199388 @default.
• W2549069008 cites W2003438913 @default.
• W2549069008 cites W2004337269 @default.
• W2549069008 cites W2004981153 @default.
• W2549069008 cites W2009007206 @default.
• W2549069008 cites W2029533968 @default.
• W2549069008 cites W2044271955 @default.
• W2549069008 cites W2049687409 @default.
• W2549069008 cites W2052975116 @default.
• W2549069008 cites W2057347731 @default.
• W2549069008 cites W2061136308 @default.
• W2549069008 cites W2063961339 @default.
• W2549069008 cites W2065087624 @default.
• W2549069008 cites W2065849886 @default.
• W2549069008 cites W2077436902 @default.
• W2549069008 cites W2090160970 @default.
• W2549069008 cites W2091715532 @default.
• W2549069008 cites W2095692554 @default.
• W2549069008 cites W2097477376 @default.
• W2549069008 cites W2105219838 @default.
• W2549069008 cites W2117074998 @default.
• W2549069008 cites W2117502397 @default.
• W2549069008 cites W2117692326 @default.
• W2549069008 cites W2135195813 @default.
• W2549069008 cites W2135409663 @default.
• W2549069008 cites W2142658272 @default.
• W2549069008 cites W2144386367 @default.
• W2549069008 cites W2150676054 @default.
• W2549069008 cites W2151876400 @default.
• W2549069008 cites W2154754979 @default.
• W2549069008 cites W2163450669 @default.
• W2549069008 cites W2180481128 @default.
• W2549069008 cites W2180814331 @default.
• W2549069008 cites W2262414037 @default.
• W2549069008 cites W2334990949 @default.
• W2549069008 cites W2471781269 @default.
• W2549069008 cites W2511999984 @default.
• W2549069008 cites W2526969304 @default.
• W2549069008 doi "https://doi.org/10.18632/oncotarget.13654" @default.
• W2549069008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5349998" @default.
• W2549069008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27902462" @default.
• W2549069008 hasPublicationYear "2016" @default.
• W2549069008 type Work @default.
• W2549069008 sameAs 2549069008 @default.
• W2549069008 citedByCount "21" @default.
• W2549069008 countsByYear W25490690082017 @default.
• W2549069008 countsByYear W25490690082018 @default.
• W2549069008 countsByYear W25490690082019 @default.
• W2549069008 countsByYear W25490690082020 @default.
• W2549069008 countsByYear W25490690082021 @default.
• W2549069008 countsByYear W25490690082022 @default.
• W2549069008 countsByYear W25490690082023 @default.
• W2549069008 crossrefType "journal-article" @default.
• W2549069008 hasAuthorship W2549069008A5030293228 @default.
• W2549069008 hasAuthorship W2549069008A5045343897 @default.
• W2549069008 hasAuthorship W2549069008A5084704940 @default.
• W2549069008 hasBestOaLocation W25490690081 @default.
• W2549069008 hasConcept C104317684 @default.
• W2549069008 hasConcept C121608353 @default.
• W2549069008 hasConcept C126322002 @default.
• W2549069008 hasConcept C134935766 @default.
• W2549069008 hasConcept C143998085 @default.
• W2549069008 hasConcept C182979987 @default.
• W2549069008 hasConcept C2778480876 @default.
• W2549069008 hasConcept C2778502085 @default.
• W2549069008 hasConcept C2779962180 @default.
• W2549069008 hasConcept C502942594 @default.
• W2549069008 hasConcept C526805850 @default.
• W2549069008 hasConcept C54355233 @default.
• W2549069008 hasConcept C71924100 @default.
• W2549069008 hasConcept C82381507 @default.
• W2549069008 hasConcept C86803240 @default.
• W2549069008 hasConceptScore W2549069008C104317684 @default.
• W2549069008 hasConceptScore W2549069008C121608353 @default.
• W2549069008 hasConceptScore W2549069008C126322002 @default.
• W2549069008 hasConceptScore W2549069008C134935766 @default.
• W2549069008 hasConceptScore W2549069008C143998085 @default.
• W2549069008 hasConceptScore W2549069008C182979987 @default.
• W2549069008 hasConceptScore W2549069008C2778480876 @default.
• W2549069008 hasConceptScore W2549069008C2778502085 @default.

• next